Mutum EML4-ALK Fusion Gene Mutation

Ana amfani da wannan kit ɗin don gano nau'ikan maye gurbi guda 12 na EML4-ALK fusion gene a cikin samfuran mutanen da ba ƙananan ƙwayoyin cutar kansar huhu ba a cikin vitro.Sakamakon gwajin don nunin asibiti ne kawai kuma bai kamata a yi amfani da shi a matsayin tushen kawai don maganin keɓantaccen mutum na marasa lafiya ba.Ya kamata ma'aikatan asibiti su yi cikakkun hukunce-hukunce kan sakamakon gwajin bisa dalilai kamar yanayin majiyyaci, alamun magunguna, amsawar jiyya, da sauran alamun gwajin gwaji.Ciwon daji na huhu shine mafi yawan ƙwayar cuta a duk duniya, kuma 80% ~ 85% na lokuta sune wadanda ba ƙananan ƙwayoyin huhu ba (NSCLC).Gene fusion na echinoderm microtubule-hade protein-kamar 4 (EML4) da anaplastic lymphoma kinase (ALK) wani labari ne manufa a cikin NSCLC, EML4 da ALK suna cikin ɗan adam P21 da P23 makada akan chromosome 2 kuma an raba su da kusan 12.7 miliyan tushe nau'i-nau'i.Aƙalla an sami bambance-bambancen fusion guda 20, daga cikinsu akwai nau'ikan fusion guda 12 a cikin Tebu 1 na gama gari, inda mutant 1 (E13; A20) ya fi yawa, sannan mutants 3a da 3b (E6; A20), suna lissafin kusan kusan. 33% da 29% na marasa lafiya tare da EML4-ALK fusion gene NSCLC, bi da bi.Masu hana ALK da Crizotinib ke wakilta wasu ƙananan ƙwayoyin cuta ne da aka yi niyya don maye gurbin kwayoyin halittar ALK.Ta hanyar hana ayyukan yankin ALK tyrosine kinase, yana toshe hanyoyin siginar da ke cikin ƙasa, ta haka ya hana ci gaban ƙwayoyin tumor, don cimma nasarar da aka yi niyya don ciwace-ciwacen daji.Nazarin asibiti ya nuna cewa Crizotinib yana da tasiri mai tasiri fiye da 61% a cikin marasa lafiya tare da maye gurbin EML4-ALK, yayin da kusan ba shi da wani tasiri ga marasa lafiya na daji.Saboda haka, gano EML4-ALK fusion maye gurbi shine jigo da tushe don jagorantar amfani da magungunan Crizotinib.